NCT06166888View on ClinicalTrials.gov

A Study of AK131 in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

130

Participants

Timeline

Start Date

January 10, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

December 31, 2028

Conditions

Solid Tumor

Interventions

DRUG

AK131

AK131 is an anti-PD-1 and CD73 bispecific antibody

Trial Locations (1)

250117

RECRUITING

Jinming Yu, Jinan

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Akeso

INDUSTRY